CRIS Current Research Information System

MARTELLI, ALBERTO MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.072
EU - Europa 8.949
AS - Asia 3.992
AF - Africa 516
SA - Sud America 36
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 2
Totale 26.588
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.050
GB - Regno Unito 2.579
CN - Cina 1.592
IT - Italia 1.424
DE - Germania 1.353
SE - Svezia 1.219
SG - Singapore 867
VN - Vietnam 797
UA - Ucraina 559
IN - India 494
FR - Francia 377
IE - Irlanda 376
RU - Federazione Russa 328
EE - Estonia 219
ZA - Sudafrica 217
TG - Togo 167
CH - Svizzera 104
JO - Giordania 79
BG - Bulgaria 71
BE - Belgio 63
HR - Croazia 55
FI - Finlandia 51
CI - Costa d'Avorio 46
NG - Nigeria 44
SC - Seychelles 36
NL - Olanda 35
AT - Austria 33
JP - Giappone 30
ID - Indonesia 29
GR - Grecia 25
IR - Iran 22
CA - Canada 19
CL - Cile 16
AU - Australia 14
HK - Hong Kong 12
RO - Romania 12
BR - Brasile 11
PK - Pakistan 11
TR - Turchia 11
LB - Libano 10
CZ - Repubblica Ceca 9
PT - Portogallo 9
PL - Polonia 8
ES - Italia 7
NZ - Nuova Zelanda 7
UZ - Uzbekistan 7
EC - Ecuador 6
HU - Ungheria 6
KR - Corea 5
LT - Lituania 5
MD - Moldavia 4
PH - Filippine 4
SA - Arabia Saudita 4
DK - Danimarca 3
EG - Egitto 3
LA - Repubblica Popolare Democratica del Laos 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
AR - Argentina 2
KZ - Kazakistan 2
LU - Lussemburgo 2
LV - Lettonia 2
NO - Norvegia 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BD - Bangladesh 1
BO - Bolivia 1
BS - Bahamas 1
DZ - Algeria 1
GL - Groenlandia 1
IL - Israele 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LK - Sri Lanka 1
MA - Marocco 1
MK - Macedonia 1
MU - Mauritius 1
MX - Messico 1
MY - Malesia 1
RS - Serbia 1
TH - Thailandia 1
TM - Turkmenistan 1
TW - Taiwan 1
Totale 26.588
Salva come PNG Salva come JPEG
Città #
Southend 2.311
Fairfield 1.818
Ashburn 1.078
Chandler 1.013
Woodbridge 913
Houston 852
Wilmington 770
Singapore 769
Seattle 756
Cambridge 616
Ann Arbor 614
Princeton 578
Santa Clara 536
Dong Ket 525
Bologna 418
Dublin 374
Boardman 351
Jacksonville 333
Nanjing 273
Westminster 253
Padova 219
Berlin 172
Lomé 167
San Diego 132
Saint Petersburg 125
Jinan 116
Beijing 108
Shenyang 101
Bremen 82
Bern 80
Amman 78
Redmond 78
Turin 77
Changsha 74
Mülheim 73
Milan 72
New York 71
Sofia 71
Nanchang 70
Hebei 67
Brussels 56
Tianjin 51
Florence 47
Abidjan 46
Helsinki 46
Abeokuta 44
Guangzhou 44
Dearborn 41
Des Moines 41
Jiaxing 41
Shanghai 40
Norwalk 39
Medford 37
Washington 37
Mahé 35
Haikou 33
Los Angeles 33
Zhengzhou 33
Falls Church 32
Redwood City 32
Rome 32
Hangzhou 27
Jakarta 26
Bühl 25
Ningbo 24
Verona 24
Olalla 23
Tokyo 22
London 21
Taiyuan 21
Taizhou 21
Kunming 19
Mountain View 19
Fuzhou 18
Vienna 18
Paris 16
Frankfurt am Main 15
San Venanzo 15
Wuhan 15
Ferrara 14
Lanzhou 14
Chicago 13
Reggio Emilia 13
Toronto 13
Frankfurt Am Main 12
Hefei 12
Chengdu 11
San Francisco 11
Wenzhou 11
Buffalo 10
Las Vegas 10
Lausanne 10
Plauen 10
Pune 10
San Giuliano Milanese 10
Amsterdam 9
Locri 9
Phoenix 9
Shenzhen 9
Tappahannock 9
Totale 18.622
Salva come PNG Salva come JPEG
Nome #
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 195
Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: from biology to therapeutic targeting. 190
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia 185
Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. 181
Characterization of biological effects in radiotherapy applications of ultra-high dose rate pulses from a plasma focus device 178
Catalytic activity of nuclear PLC-beta(1) is required for its signalling function during C2C12 differentiation. 177
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235, against T-cell acute lymphoblastic leukemia. 176
INPP4B overexpression and c-KIT downregulation in human achalasia. 173
Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene 169
Assessment of the effect of sphingosine kinase inhibitors on apoptosis, unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. 163
Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. 160
Early biological effects of ultra-high compare to standard dose rate of X-rays on a radioresistant cell line 153
Inositide signaling in the nucleus: From physiology to pathology. 153
Therapeutic targeting of CK2 in acute and chronic leukemias. 153
Activity of the Selective IκB kinase Inhibitor BMS-345541 against T-Cell Acute Lymphoblastic Leukemia: involvement of FOXO3a 152
COMBINING DOT1L INHIBITOR EPZ-5676 WITH SORAFENIB TO TREAT MLL-REARRANGED (MLL-R) PEDIATRIC ACUTE MYELOID LEUKEAMIA (AML) 152
B-all complexity: Is targeted therapy still a valuable approach for pediatric patients? 146
Inositide signaling: Nuclear targets and involvement in myelodysplastic syndromes 145
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. 145
null 144
Autophagy in acute leukemias: a double-edged sword with important therapeutic implications. 142
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. 142
The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma 142
Toxicity of antimony trioxide nanoparticles on human hematopoietic progenitor cells and comparison to cell lines. 140
Improving nelarabine efficacy in T-cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. 139
Revisiting nuclear phospholipase C signalling in MDS 138
Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS 138
Advances in Targeting Signal Transduction Pathways. 136
Nuclear inositides: facts and perspectives. 134
Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs 134
Antioxidants in the prevention of UVB-induced keratynocyte apoptosis. 134
Multiple forms of PKR present in the nuclei of acute leukemia cells represent an active kinase that is responsive to stress 133
Application of flow cytometry to molecular medicine: Detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts 133
Caspase-9 is the upstream caspase activated by 8-methoxypsoralen and ultraviolet-A radiation treatment of Jurkat T leukemia cells and normal T lymphocytes 131
Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells 131
Intranuclear 3'-phosphoinositide metabolism and Akt signaling: New mechanisms for tumorigenesis and protection against apoptosis? 130
Enhancing radiosensitivity of melanoma cells through very high dose rate pulses released by a plasma focus device 129
Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy 128
COMBINAZIONE DI EPZ-5676 E SORAFENIB COME NUOVA STRATEGIA TERAPEUTICA PER IL TRATTAMENTO DELLE LEUCEMIE ACUTE MIELOIDI PEDIATRICHE 128
Cutting edge: the role of mTOR signaling in laminopathies. 128
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling 127
Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells. 126
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. 126
Nuclear protein kinase C isoforms and apoptosis 125
Nuclear phospholipase C beta1 and cellular differentiation. 124
Monitoring of FLT3 phosphorylation status and its response to drugs by flow cytometry in AML blast cells 124
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia 124
Regulation of nuclear phospholipase C activity 123
Quantitative immunodetection of key elements of polyphosphoinositide signal transduction in osteoblasts from arthritic patients shows a direct correlation with cell proliferation 123
Expression of phospholipase C beta family isoenzymes in C2C12 myoblasts during terminal differentiation. 122
Frequent Elevation of Akt Kinase Phosphorylation in Blood Marrow and Peripheral Blood Mononuclear Cells from High Risk myelodysplastic Syndrome Patients 121
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. 121
Antiapoptotic role of p38 mitogen activated protein kinase in Jurkat T cells and normal human T lymphocytes treated with 8-methoxypsoralen and ultraviolet-A radiation 121
Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells 121
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction 120
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. 120
Nuclear inositol lipid metabolism: more than just second messenger generation? 119
Caspase-dependent cleavage of 170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid CEM cells 119
The Emerging Role of the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology. 118
A novel deleterious PTEN mutation in a patient with early-onset bilateral breast cancer. 118
ASSESSMENT OF THE EFFECT OF SPHINGOSINE KINASE INHIBITORS ON APOPTOSIS, UNFOLDED PROTEIN RESPONSE AND AUTOPHAGY OF T-ACUTE LYMPHOBLASTIC LEUKEMIA CELLS: INDICATIONS FOR NOVEL THERAPEUTICS 118
Detection of serine 473 phosphorylated Akt in acute myeloid leukaemia blasts by flow cytometry 117
Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. 116
The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage 115
Nuclear inositide signaling in myelodysplastic syndromes. 115
Identification of a functional nuclear export sequence in diacylglycerol kinase-zeta. 115
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-ami ne (A443654) in T-cell acute lymphoblastic leukemia. 114
Aberrant Proliferative and Apoptotic Pathways in Acute Lymphoblastic Leukemia (ALL):Molecular Therapies to Overcome Chemo-Resistance. 113
MYCN is a novel oncogenic target in pediatric T-cell Acute Lymphoblastic Leukemia 113
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. 113
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 113
Nuclear protein kinase C 112
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. 112
Physiology and pathology of nuclear phospholipase C beta1 112
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 112
Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias 111
Therapeutic targeting of mTOR in T-cell acute lymphoblastic leukemia: An update. 111
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. 110
Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies 110
Inositide-dependent phospholipase C signaling mimics insulin in skeletal muscle differentiation by affecting specific regions of the cyclin D3 promoter 110
Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics 110
Lamin A and prelamin A counteract invasiveness of osteosarcoma cells 110
Novel 2'-substituted, 3'-deoxy-phosphatidyl-myo-inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/Akt pathway 109
TIS2/BTG2/PC3 and cyclin D1 are key determinants of nuclear diacylglycerol kinase-zeta-dependent cell cycle arrest 109
Cancer therapy and treatments during COVID-19 era 109
Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. 108
Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. 108
Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. 108
Nuclear diacylglycerol kinase-theta is activated in response to nerve growth factor stimulations of PC12 cells 107
Akt is a therapeutic target in cancer 107
Nuclear phosphoinositides and their roles in cell biology and disease. 107
Therapeutic targeting of polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblstic leukemia. 107
Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway 107
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells 107
Sparc localizes to the blebs of hobit cells and human primary osteoblasts 106
Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells—Power of nutraceuticals 106
Targeting CTLA-4 by its recombinant ligands CD80/CD86: Perspectives towards the development of a novel anti-tumor therapeutic approach. 106
The Combination of AHCC and ETAS Decreases Migration of Colorectal Cancer Cells, and Reduces the Expression of LGR5 and Notch1 Genes in Cancer Stem Cells: A Novel Potential Approach for Integrative Medicine 106
Significance of subnuclear licalization of key players of inositol lipid cycle. 105
The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis 105
Totale 12.831
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.555
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.555
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.641 0 0 0 0 728 781 917 921 1.085 490 295 424
2020/20213.414 751 289 131 129 67 159 67 217 287 182 165 970
2021/20225.039 553 135 348 378 446 292 156 352 152 605 808 814
2022/20234.776 549 622 260 688 336 351 213 261 788 89 406 213
2023/20241.386 83 214 124 107 150 293 74 65 43 100 52 81
2024/20252.667 120 849 510 338 850 0 0 0 0 0 0 0
Totale 27.279